All of the following are well-known ototoxic drugs except?
Red urine without RBCs is seen in which of the following conditions?
Which drug may lead to hemolysis in a child with G6PD deficiency?
Which instructions should be included in the teaching care plan for a patient with cystitis receiving phenazopyridine?
Which one of the following drugs is associated with the development of a lupus-like syndrome, especially in patients identified as "slow acetylators"?
Bone marrow aplasia is not seen with which of the following drugs?
Pharmacovigilance is done for monitoring what?
Which of the following statements regarding aspirin toxicity is true?
Which of the following drugs does NOT cause cholestasis with inflammation of bile ducts?
Which one of the following is ineffective in acute iron toxicity?
Explanation: **Explanation:** Ototoxicity refers to drug-induced damage to the inner ear, specifically affecting the cochlea (hearing) or the vestibular apparatus (balance). **Why Acetaminophen is the correct answer:** Acetaminophen (Paracetamol) is a centrally acting analgesic and antipyretic. Unlike Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), it does not significantly inhibit peripheral cyclooxygenase (COX) in a way that affects the microvasculature of the inner ear. It is considered safe for the ears and is not associated with clinical ototoxicity. **Why the other options are wrong:** * **Aspirin (Salicylates):** High doses of aspirin cause reversible ototoxicity, typically presenting as **tinnitus** (ringing in the ears) and symmetrical sensorineural hearing loss. It acts by inhibiting COX and altering the electrochemical gradient in the stria vascularis. * **Aminoglycosides (e.g., Gentamicin, Amikacin):** These are notorious for causing **irreversible** ototoxicity. They accumulate in the perilymph and destroy sensory hair cells via oxidative stress. Gentamicin is more vestibulotoxic, while Amikacin is more cochleotoxic. * **Loop Diuretics (e.g., Furosemide, Ethacrynic acid):** These cause ototoxicity by altering the electrolyte composition of the endolymph in the stria vascularis. This is usually reversible but can be permanent if given in high doses intravenously or combined with aminoglycosides. **High-Yield Clinical Pearls for NEET-PG:** * **Synergistic Toxicity:** The risk of permanent hearing loss increases significantly when **Loop Diuretics** and **Aminoglycosides** are administered together. * **Cisplatin:** A platinum-based chemotherapeutic agent that is a very common "except" option in ototoxicity questions (it is highly ototoxic). * **Vancomycin:** Often cited as ototoxic, though modern purified formulations carry a much lower risk unless used with other ototoxic agents. * **Quinine/Chloroquine:** Can cause "Cinchonism," which includes tinnitus and hearing loss.
Explanation: ### Explanation The presence of red urine without red blood cells (RBCs) on microscopy is a classic clinical finding that distinguishes **discoloration (pseudohematuria)** from true hematuria. **1. Why Option D is Correct:** **Rifampicin**, a key bactericidal drug used in Tuberculosis (RNTCP/NTEP), is a highly lipid-soluble, macrocyclic antibiotic. It is excreted through bile and urine. A unique characteristic of Rifampicin is its ability to cause a **harmless, reddish-orange discoloration** of all body secretions, including urine, sweat, saliva, and tears. Since this is due to the pigment of the drug itself and not due to bleeding, microscopy will show **zero RBCs**. **2. Why Incorrect Options are Wrong:** * **Lupus Nephritis (A):** This is an inflammatory glomerulonephritis. It typically presents with **microscopic or macroscopic hematuria**, meaning RBCs (often dysmorphic) will be present in the urine. * **Pyelonephritis (B):** This is an upper urinary tract infection. It is characterized by pyuria (WBCs) and frequently involves **hematuria** due to mucosal inflammation. * **Hemolytic Uremic Syndrome (C):** HUS involves microangiopathic hemolytic anemia and acute kidney injury. It typically presents with **hematuria** and hemoglobinuria. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other causes of red urine without RBCs:** Myoglobinuria (rhabdomyolysis), Hemoglobinuria (intravascular hemolysis), and ingestion of Beetroot (Beeturia) or Senna. * **Rifampicin Counseling:** Always counsel patients that orange-red urine is a side effect, not a sign of toxicity, to ensure treatment adherence. * **Mechanism of Rifampicin:** Inhibits DNA-dependent RNA polymerase. * **Drug Interactions:** Rifampicin is a potent **Cytochrome P450 inducer**, leading to decreased plasma levels of drugs like Warfarin and Oral Contraceptive Pills (OCPs).
Explanation: ### Explanation **Correct Option: B. Primaquine** **Mechanism of Hemolysis in G6PD Deficiency:** Glucose-6-Phosphate Dehydrogenase (G6PD) is the rate-limiting enzyme in the pentose phosphate pathway, responsible for generating **NADPH**. In RBCs, NADPH is essential to maintain **reduced glutathione**, which neutralizes reactive oxygen species (ROS). **Primaquine** is an oxidizing agent. In G6PD-deficient individuals, the inability to regenerate reduced glutathione leads to the oxidation of hemoglobin into insoluble precipitates called **Heinz bodies**. These damage the RBC membrane, leading to acute hemolytic anemia. This is a classic example of **Pharmacogenetics**. **Analysis of Incorrect Options:** * **A. Penicillin:** While Penicillin can cause immune-mediated hemolytic anemia (Type II Hypersensitivity), it is not an oxidizing agent and does not trigger G6PD-related hemolysis. * **C. Ceftriaxone:** A third-generation cephalosporin that does not possess significant oxidizing potential. * **D. Erythromycin:** A macrolide antibiotic that is safe in G6PD deficiency. **High-Yield Clinical Pearls for NEET-PG:** * **Other Trigger Drugs:** Dapsone (highest risk), Nitrofurantoin, Sulfonamides (e.g., Co-trimoxazole), and Ciprofloxacin. * **Non-Drug Triggers:** Fava beans (Favism) and infections (most common cause of hemolysis). * **Peripheral Smear Findings:** Look for **Heinz bodies** (denatured hemoglobin) and **Bite cells** (deformed RBCs after splenic macrophages remove Heinz bodies). * **Inheritance:** G6PD deficiency is an **X-linked recessive** disorder, predominantly affecting males. * **Primaquine Rule:** Always screen for G6PD deficiency before initiating Primaquine for the radical cure of *P. vivax* or *P. ovale*.
Explanation: **Explanation:** Phenazopyridine is a **urinary tract analgesic** used for the symptomatic relief of pain, burning, urgency, and frequency associated with lower urinary tract infections (cystitis). It is not an antibiotic and has no antibacterial activity. **Why Option D is Correct:** Phenazopyridine is intended for **short-term symptomatic relief** only (usually 2 days). Once the pain and discomfort are relieved by the concurrent antibiotic therapy, the drug should be discontinued. Prolonged use can mask the symptoms of a worsening infection or lead to drug accumulation and toxicity. **Analysis of Incorrect Options:** * **Option A:** While it is true that phenazopyridine causes a harmless **orange-red discoloration** of urine (and can stain contact lenses/clothing), this is a side effect to be aware of, but the *primary* clinical instruction regarding the course of therapy is its discontinuation once symptoms resolve. * **Option B:** The drug should be taken **after meals** to prevent GI upset. It works through a local anesthetic effect on the urinary mucosa after being excreted; taking it "just before urination" is pharmacologically incorrect as it requires time to be metabolized and excreted. * **Option C:** Antibiotics must always be completed for the full prescribed course to prevent antibiotic resistance and recurrence, regardless of when symptoms disappear. **NEET-PG High-Yield Pearls:** * **Mechanism:** Local anesthetic action on the mucosa of the urinary tract. * **Key Side Effect:** Orange-red discoloration of urine (often confused with hematuria). * **Serious Toxicity:** In patients with renal impairment, it can cause **Methemoglobinemia** and hemolytic anemia. * **Contraindication:** It is contraindicated in patients with a GFR < 50 mL/min (Renal Insufficiency).
Explanation: ### Explanation **Correct Option: D. Procainamide** Procainamide is a Class IA antiarrhythmic drug notorious for causing **Drug-Induced Lupus Erythematosus (DILE)**. The underlying mechanism involves its metabolism via the **N-acetyltransferase (NAT)** enzyme. In the liver, procainamide is acetylated to N-acetylprocainamide (NAPA). Patients who are **"slow acetylators"** have a genetic deficiency of this enzyme, leading to the accumulation of the parent drug. This excess drug undergoes alternative oxidative metabolism, forming reactive metabolites that trigger an autoimmune response, typically manifesting as joint pain, fever, and pleuritis. **Analysis of Incorrect Options:** * **A. Amiodarone:** Known for causing pulmonary fibrosis, thyroid dysfunction (hypo/hyperthyroidism), and corneal microdeposits, but not a lupus-like syndrome. * **B. Clonidine:** An alpha-2 agonist used for hypertension; its primary side effects include sedation, dry mouth, and rebound hypertension upon abrupt withdrawal. * **C. Nitroglycerin:** A vasodilator used in angina; common side effects include throbbing headache, flushing, and orthostatic hypotension. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for DILE drugs:** "**S**hip **H**as **P**ushed **M**e" (**S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide, **P**henytoin, **M**ethyldopa). * **Serology:** DILE is characterized by the presence of **Anti-Histone Antibodies** (95% sensitivity). Unlike systemic lupus (SLE), Anti-dsDNA antibodies are usually absent. * **Prognosis:** Symptoms typically resolve upon discontinuation of the offending drug. * **Procainamide specific:** It has the highest risk of inducing ANA (Antinuclear Antibody) positivity, occurring in up to 80% of patients over time.
Explanation: **Explanation:** Bone marrow aplasia (aplastic anemia) is a serious condition characterized by the pancytopenia of peripheral blood and a hypocellular bone marrow. In the context of pharmacology, it is often a result of drug-induced myelosuppression. **Why Levodopa is the Correct Answer:** **Levodopa** is a precursor of dopamine used in the treatment of Parkinson’s disease [1]. Its primary side effects are gastrointestinal (nausea, vomiting), cardiovascular (arrhythmias, orthostatic hypotension), and neurological (dyskinesias, hallucinations) [1], [2]. It is **not** associated with bone marrow suppression or aplastic anemia [1]. **Analysis of Incorrect Options:** * **Azathioprine:** This is a potent immunosuppressant (prodrug of 6-mercaptopurine). Its primary dose-limiting toxicity is **bone marrow suppression**, leading to leukopenia and occasionally full aplasia, especially in patients with Thiopurine Methyltransferase (TPMT) deficiency. * **Furosemide:** While primarily a loop diuretic, sulfonamide-derived drugs like Furosemide can rarely cause idiosyncratic bone marrow suppression and blood dyscrasias. * **Chloramphenicol:** This is a classic "high-yield" cause of bone marrow aplasia. It causes two types of toxicity: a dose-dependent, reversible suppression and a rare, **dose-independent, irreversible aplastic anemia** which can be fatal. **NEET-PG High-Yield Pearls:** 1. **Chloramphenicol** is the most notorious drug associated with idiosyncratic aplastic anemia. 2. **Gold salts, Phenylbutazone, and Carbamazepine** are other frequent culprits of drug-induced aplastic anemia. 3. **TPMT testing** is recommended before starting Azathioprine to prevent life-threatening myelosuppression. 4. **Gray Baby Syndrome** is another specific toxicity of Chloramphenicol due to deficient glucuronidation in neonates.
Explanation: **Explanation:** **Pharmacovigilance (PV)** is defined by the WHO as the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. **Why Option C is Correct:** The primary objective of pharmacovigilance is to ensure **drug safety**. While Phase I-III clinical trials identify common side effects, they involve a limited number of participants. Once a drug is marketed (Phase IV), pharmacovigilance monitors its effects in the general population to identify rare, delayed, or unexpected adverse drug reactions (ADRs), ensuring the long-term safety profile of the medication. **Why Other Options are Incorrect:** * **Option A & B:** Drug pricing and unethical practices (like illegal marketing or clinical trial fraud) are overseen by regulatory and legal bodies (e.g., NPPA for pricing in India, or CDSCO/Ethics Committees for conduct), not by pharmacovigilance systems. * **Option D:** Monitoring students is an academic/administrative function and has no relation to clinical pharmacology. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacovigilance Programme of India (PvPI):** Launched in 2010; the National Coordinating Centre is the **Indian Pharmacopoeia Commission (IPC)**, Ghaziabad. * ** Uppsala Monitoring Centre (UMC), Sweden:** The international hub for global ADR monitoring. * **Spontaneous Reporting:** The most common method used in pharmacovigilance for reporting ADRs by healthcare professionals. * **Yellow Form:** The standard tool used for reporting suspected ADRs. * **Signal Detection:** The process of identifying a potential causal association between a drug and an adverse event that was previously unknown.
Explanation: **Explanation:** **1. Why Option A is Correct:** Tinnitus (ringing in the ears) is a classic, early, and sensitive indicator of salicylate toxicity (salicylism). It occurs due to the inhibition of cyclooxygenase (COX) and the subsequent alteration of ion transport in the stria vascularis of the cochlea, alongside increased pressure in the labyrinth. In clinical practice, the onset of tinnitus often serves as a warning sign to reduce the dose of aspirin. **2. Analysis of Incorrect Options:** * **Option B:** While 10–30 g is a significant amount, it is actually the **lethal dose** for adults, not just the threshold for poisoning. Mild toxicity (salicylism) can occur at much lower therapeutic doses if taken chronically. * **Option C:** While hyperthermia and tachypnea do occur, they are typically seen in **moderate to severe toxicity**. Tachypnea results from direct stimulation of the respiratory center, and hyperthermia results from the uncoupling of oxidative phosphorylation. Tinnitus precedes these systemic metabolic derangements. * **Option D:** Aspirin causes a **qualitative platelet defect** (by irreversibly inhibiting COX-1 and thromboxane A2 synthesis), leading to an increased bleeding time. It does not typically cause a decrease in platelet count (thrombocytopenia). **High-Yield Clinical Pearls for NEET-PG:** * **Acid-Base Balance:** Aspirin toxicity causes a unique **mixed acid-base disturbance**: Respiratory Alkalosis (early, due to hyperventilation) + Metabolic Acidosis (later, due to accumulation of organic acids). * **Management:** Treatment involves **Urinary Alkalinization** (using IV Sodium Bicarbonate) to enhance the excretion of salicylates (ion trapping). * **Done Nomogram:** Used to estimate the severity of toxicity based on serum salicylate levels (though clinical correlation is preferred).
Explanation: **Explanation:** Drug-induced liver injury (DILI) can manifest as hepatocellular necrosis, steatosis, or cholestasis. **Cholestatic jaundice** is characterized by the impairment of bile flow, which can occur with or without inflammation of the bile ducts (vanishing bile duct syndrome). **Why Astemizole is the correct answer:** Astemizole is a second-generation H1-antihistamine. While it was notorious for causing **QT interval prolongation** and *Torsades de Pointes* (leading to its withdrawal from many markets), it is not associated with cholestatic liver injury or bile duct inflammation. **Analysis of Incorrect Options:** * **Erythromycin:** Specifically the **estolate salt**, is a classic cause of cholestatic hepatitis. It typically presents with right upper quadrant pain and jaundice, mimicking acute cholecystitis. * **Amoxicillin-Clavulanic Acid:** This is one of the most common causes of drug-induced cholestatic liver injury worldwide. The injury is primarily attributed to the **clavulanic acid** component and often presents several weeks after stopping the therapy. * **Trimethoprim-Sulphamethoxazole (TMP-SMX):** Sulfonamides are well-known triggers for idiosyncratic liver injury, frequently presenting as mixed hepatocellular-cholestatic patterns with ductal involvement. **High-Yield Clinical Pearls for NEET-PG:** * **Pure Cholestasis (without inflammation):** Classically caused by **Anabolic steroids** and **Oral Contraceptive Pills (OCPs)**. * **Cholestatic Hepatitis (with inflammation):** Associated with **Erythromycin, Chlorpromazine,** and **Amoxicillin-Clavulanic acid**. * **Astemizole & Terfenadine:** High-yield for their **cardiotoxicity** (prolonged QT) when co-administered with CYP3A4 inhibitors like Ketoconazole or Macrolides.
Explanation: **Explanation:** Acute iron toxicity is a medical emergency characterized by gastrointestinal hemorrhage, metabolic acidosis, and multi-organ failure. The management focuses on preventing absorption and enhancing elimination through specific chelation. **Why BAL is the correct answer:** **BAL (British Anti-Lewisite/Dimercaprol)** is ineffective and contraindicated in iron toxicity. Dimercaprol forms a complex with iron that is **nephrotoxic**. It is primarily used for heavy metals like arsenic, mercury, and lead. Using it for iron poisoning can exacerbate renal damage rather than resolve the toxicity. **Analysis of Incorrect Options:** * **Desferrioxamine:** This is the **specific antidote of choice** for acute iron toxicity. It is administered parenterally and binds free iron to form ferrioxamine, which is excreted in the urine (often turning it a "vin-rose" color). * **Whole Bowel Irrigation (WBI):** Since iron tablets are radiopaque and do not bind to activated charcoal, WBI using Polyethylene Glycol (PEG) is the preferred method to mechanically flush unabsorbed tablets from the GI tract. * **Deferasirox:** This is an **oral iron chelator**. While primarily used for chronic iron overload (e.g., Thalassemia), it is pharmacologically active against iron, unlike BAL. However, Desferrioxamine remains the gold standard for *acute* cases. **High-Yield Clinical Pearls for NEET-PG:** 1. **Activated Charcoal:** Does **not** bind iron; it is useless in pure iron poisoning. 2. **Vin-Rose Urine:** A classic sign during Desferrioxamine therapy indicating the excretion of the iron-chelate complex. 3. **Abdominal X-ray:** Useful in diagnosis because iron tablets are radiopaque. 4. **Toxicity Stages:** Remember the "latent period" (Stage 2) where the patient appears to improve before crashing into hepatic failure and shock.
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free